Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

118.81USD
23 Sep 2016
Change (% chg)

$-0.65 (-0.54%)
Prev Close
$119.46
Open
$119.41
Day's High
$119.60
Day's Low
$118.71
Volume
4,772,980
Avg. Vol
6,681,233
52-wk High
$126.07
52-wk Low
$89.90

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $325,049.50
Shares Outstanding(Mil.): 2,735.88
Dividend: 0.80
Yield (%): 2.69

Financials

  JNJ Industry Sector
P/E (TTM): 22.13 36.61 36.60
EPS (TTM): 5.37 -- --
ROI: 13.31 14.46 13.91
ROE: 20.93 15.26 14.82

Abbott to sell its eye care business to J&J for about $4.33 billion

Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

Sep 16 2016

UPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln

Sept 16 Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

Sep 16 2016

BRIEF-Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln

* Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017.

Sep 16 2016

BRIEF-Johnson & Johnson to buy Abbott Medical Optics for $4.325 bln

* Johnson & Johnson announces agreement to acquire Abbott Medical Optics

Sep 16 2016

Abbott in talks to sell its eye-surgery business to J&J - WSJ

Sept 16 Abbott Laboratories is in talks to sell its eye-surgery business to Johnson & Johnson, the Wall Street Journal reported, citing sources familiar with the matter.

Sep 16 2016

BRIEF-WellDoc announces agreement with LifeScan

* WellDoc announces agreement with LifeScan Inc, a Johnson & Johnson diabetes care company, to finalize commercial partnership to deliver combined, best-in-class digital therapeutic solution for patients with type 2 diabetes Source text for Eikon: Further company coverage:

Sep 13 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

Aug 22 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

Aug 22 2016

BRIEF-Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing

* Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16 Source text (http://bit.ly/2biMrcb) Further company coverage:

Aug 19 2016

BRIEF-Johnson & Johnson announces ruling related to Remicade

* Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing

Aug 17 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.